XTXiao‐Qi Tian

Xiao‐Qi Tian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiao‐Qi Tian has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Fang Xie

    Department of Ultrasound The First Medical Center of PLA General Hospital Beijing China

    1 shared publication
  • Jing Xiao

    Department of Ultrasound, The First Medical Center of Chinese PLA General Hospital, Beijing, China

    1 shared publication
  • Lin Yan

    Department of Ultrasound, First Medical Center, Chinese PLA General Hospital

    1 shared publication
  • Mingbo Zhang

    Department of Ultrasound, First Medical Center, Chinese PLA General Hospital, Beijing, China

    1 shared publication
  • Ya‐Qiong Zhu

    Department of Ultrasound The First Medical Center of PLA General Hospital Beijing China

    1 shared publication
  • Ying Zhang

    From the Departments of Ultrasound (Yan Zhang, W.L., J.H.Z., Ying Zhang, H.Y.H., Y.K.L.) and Pathology (J.L.), Division of First Medical Center, Chinese People’s Liberation Army General Hospital, 28 Fuxing Rd, Beijing 100853, China; and Department of Ultrasound, Division of Second Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, China (Y.Y.L.).

    1 shared publication

Latest Publications

  • Targeting Diagnosis of High‐Risk Papillary Thyroid Carcinoma Using Ultrasound Contrast Agent With the BRAFV600E Mutation

    by Fang Xie, Lin Yan, Yi‐Ming Li, Yu Lan, Jing Xiao, Ming‐Bo Zhang, Zhuang Jin, Ying Zhang, Xiao‐Qi Tian, Ya‐Qiong Zhu, et al.

    Objective High-risk papillary thyroid carcinoma (PTC) patients with BRAF mutation have lymph node and distant metastasis and poor prognosis. Therefore, this study aims to develop a targeted ultrasound contrast agent for the BRAF(V600E) mutation to screen high-risk PTC at early stage. Methods The targeted lipid nanobubbles carrying BRAF(V600E) antibody were prepared using thin film hydration-sonication and avidin-biotin binding methods. The physicochemical properties and stability of the targeted nanobubbles were detected by transmission electron microscopy, atomic force microscopy, and confocal laser scanning microscopy. The target binding abilities of the targeted nanobubbles in the PTC cells (B-CPAP) overexpressed mutant BRAF(V600E) were evaluated by immunofluorescence staining, quantitative real-time polymerase chain reaction, western blot, and fluorescence microscopy. After PTC tumor models overexpressed mutant BRAF(V600E) were established, the enhanced images of targeted lipid nanobubbles and untargeted lipid nanobubbles on PTC tumors in nude mice were observed using contrast-enhanced ultrasound imaging. Results The targeted lipid nanobubbles revealed uniform, round morphology, and good stability with a nanoscale size. Besides, BRAF(V600E) monoclonal antibody was observed to be combined on the surface of lipid nanobubbles. Furthermore, the targeted nanobubbles had a good targeting diagnosis ability in PTC cells with BRAF(V600E) overexpression. Moreover, the targeted nanobubbles had better ultrasound enhancement and peak intensity of the time-intensity curve (P < .001) in PTC tumors with BRAF(V600E) overexpression as compared to the untargeted lipid nanobubbles. Conclusion The targeted lipid nanobubbles carrying BRAF(V600E) antibody could be regarded as a potential targeted ultrasound contrast agent for the diagnosis of high-risk PTC.